Oragenics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 20.66 million compared to USD 14.29 million a year ago. Basic loss per share from continuing operations was USD 9.18 compared to USD 7.11 a year ago.

Diluted loss per share from continuing operations was USD 9.18 compared to USD 7.11 a year ago.